Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan;36(1):11-6.
doi: 10.1097/RLU.0b013e3181feeb48.

FDG PET/CT evaluation of treatment response in patients with recurrent colorectal cancer

Shamim Ahmed Shamim  1 , Rakesh Kumar, Varun Shandal, Dhanapathi Halanaik, Guresh Kumar, Chandra Shekhar Bal, Arun Malhotra
Affiliations

FDG PET/CT evaluation of treatment response in patients with recurrent colorectal cancer

Shamim Ahmed Shamim et al. Clin Nucl Med. 2011 Jan.

Abstract

Aim: to evaluate the treatment response in patients with recurrent colorectal cancer (CRC) using FDG PET/CT.

Materials and methods: a total of 32 recurrent CRC patients (21 males, 11 females; mean age, 52.8 years) were included in this retrospective study. All patients underwent a baseline and follow-up FDG PET/CT scans after chemotherapy. Of 32 patients, 23 patients had follow-up carcinoembryonic antigen (CEA) levels.

Results: on qualitative analysis of baseline and follow-up FDG PET/CT studies, there were 20 nonresponders and 12 were responders. On quantitative analysis, there were 19 nonresponders and 13 were responders. In responders, baseline and follow-up mean SUV(max) were 11.8 ± 10.1 and 3.7 ± 4.1, respectively (significant decrease, P = 0.001). Among nonresponders, baseline and follow-up mean SUV(max) were 8.1 ± 5.2 and 14.1 ± 9.0, respectively (significant increase, P = 0.003). There was no association between response and different factors like age, sex, diagnosis, extent of the lesions, and number of lesions.

Conclusion: FDG PET/CT appears to be useful modality in evaluating chemotherapy response and can differentiate responders from nonresponders in recurrent CRC patients.

PubMed Disclaimer

Substances